Frontiers in Oncology (Oct 2024)
Revising cancer incidence in a Central European country: a Hungarian nationwide study between 2011–2019 based on a health insurance fund database
- Zoltán Kiss,
- Zoltán Kiss,
- Tamás G. Szabó,
- Csaba Polgár,
- Csaba Polgár,
- Zsolt Horváth,
- Péter Nagy,
- Péter Nagy,
- Péter Nagy,
- Ibolya Fábián,
- Ibolya Fábián,
- Valéria Kovács,
- György Surján,
- György Surján,
- Zsófia Barcza,
- István Kenessey,
- István Kenessey,
- András Wéber,
- István Wittmann,
- Gergő Attila Molnár,
- Eszter Gyöngyösi,
- Angéla Benedek,
- Eugenia Karamousouli,
- Zsolt Abonyi-Tóth,
- Zsolt Abonyi-Tóth,
- Renáta Bertókné Tamás,
- Diána Viktória Fürtős,
- Krisztina Bogos,
- Judit Moldvay,
- Judit Moldvay,
- Gabriella Gálffy,
- Lilla Tamási,
- Veronika Müller,
- Zoárd Tibor Krasznai,
- Gyula Ostoros,
- Zsolt Pápai-Székely,
- Anikó Maráz,
- Gabriella Branyiczkiné Géczy,
- Lászlóné Hilbert,
- Láśzló Tamás Berki,
- György Rokszin,
- Zoltán Vokó,
- Zoltán Vokó,
- Zoltán Vokó
Affiliations
- Zoltán Kiss
- MSD Pharma Hungary Ltd, Budapest, Hungary
- Zoltán Kiss
- Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary
- Tamás G. Szabó
- MSD Pharma Hungary Ltd, Budapest, Hungary
- Csaba Polgár
- National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary
- Csaba Polgár
- Department of Oncology, Semmelweis University, Budapest, Hungary
- Zsolt Horváth
- Department of Oncology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary
- Péter Nagy
- Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
- Péter Nagy
- Department of Anatomy and Histology, HUN-REN–UVMB Laboratory of Redox Biology Research Group, University of Veterinary Medicine, Budapest, Hungary
- Péter Nagy
- Chemistry Coordinating Institute, University of Debrecen, Debrecen, Hungary
- Ibolya Fábián
- RxTarget Ltd., Szolnok, Hungary
- Ibolya Fábián
- 0University of Veterinary Medicine, Budapest, Hungary
- Valéria Kovács
- RxTarget Ltd., Szolnok, Hungary
- György Surján
- 1Department of Deputy Chief Medical Officer II., National Public Health Center, Budapest, Hungary
- György Surján
- 2Institute of Digital Health Sciences, Semmelweis University, Budapest, Hungary
- Zsófia Barcza
- 3Syntesia Medical Communications Ltd, Budapest, Hungary
- István Kenessey
- 4Hungarian National Cancer Registry and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
- István Kenessey
- 5Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
- András Wéber
- 4Hungarian National Cancer Registry and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
- István Wittmann
- Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary
- Gergő Attila Molnár
- Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary
- Eszter Gyöngyösi
- MSD Pharma Hungary Ltd, Budapest, Hungary
- Angéla Benedek
- MSD Pharma Hungary Ltd, Budapest, Hungary
- Eugenia Karamousouli
- MSD Pharma Hungary Ltd, Budapest, Hungary
- Zsolt Abonyi-Tóth
- RxTarget Ltd., Szolnok, Hungary
- Zsolt Abonyi-Tóth
- 0University of Veterinary Medicine, Budapest, Hungary
- Renáta Bertókné Tamás
- 1Department of Deputy Chief Medical Officer II., National Public Health Center, Budapest, Hungary
- Diána Viktória Fürtős
- 1Department of Deputy Chief Medical Officer II., National Public Health Center, Budapest, Hungary
- Krisztina Bogos
- 6National Korányi Institute of Pulmonology, Budapest, Hungary
- Judit Moldvay
- 71st Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary
- Judit Moldvay
- 8Department of Pulmonology, Albert Szent-Györgyi Medical Centre, University of Szeged, Szeged, Hungary
- Gabriella Gálffy
- 9Department of Pulmonology, Pulmonology Hospital Törökbálint, Törökbálint, Hungary
- Lilla Tamási
- 0Department of Pulmonology, Semmelweis University, Budapest, Hungary
- Veronika Müller
- 0Department of Pulmonology, Semmelweis University, Budapest, Hungary
- Zoárd Tibor Krasznai
- 1Faculty of Medicine, Department of Obstetrics and Gynecology, University of Debrecen, Debrecen, Hungary
- Gyula Ostoros
- 6National Korányi Institute of Pulmonology, Budapest, Hungary
- Zsolt Pápai-Székely
- 2Fejér County Szent György, University Teaching Hospital, Székesfehérvár, Hungary
- Anikó Maráz
- 3Department of Oncotherapy, University of Szeged, Szeged, Hungary
- Gabriella Branyiczkiné Géczy
- 4Department of Population Statistics, Hungarian Central Statistical Office, Budapest, Hungary
- Lászlóné Hilbert
- 4Department of Population Statistics, Hungarian Central Statistical Office, Budapest, Hungary
- Láśzló Tamás Berki
- 5Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
- György Rokszin
- RxTarget Ltd., Szolnok, Hungary
- Zoltán Vokó
- 5Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
- Zoltán Vokó
- 6Syreon Research Institute, Budapest, Hungary
- Zoltán Vokó
- 7Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary
- DOI
- https://doi.org/10.3389/fonc.2024.1393132
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundThe nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019.MethodsUsing data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospective study analyzed newly diagnosed malignancies between Jan 1, 2011, and Dec 31, 2019. Age-standardized incidence and mortality rates were calculated for all and for different tumor types using both the 1976 and 2013 European Standard Populations (ESP).FindingsThe number of newly diagnosed cancer cases decreased from 60,554 to 56,675 between 2011–2019. Age-standardized incidence rates were much lower in 2018, than previously estimated (475.5 vs. 580.5/100,000 person-years [PYs] in males and 383.6 vs. 438.5/100,000 PYs in females; ESP 1976). All-site cancer incidence showed a mean annual decrease of 1.9% (95% CI: 2.4%-1.4%) in men and 1.0% (95% CI:1.42%-0.66%) in women, parallel to mortality trends (-1.6% in males and -0.6% in females; ESP 2013). In 2018, the highest age-standardized incidence rates were found for lung (88.3), colorectal (82.2), and prostate cancer (62.3) in men, and breast (104.6), lung (47.7), and colorectal cancer (45.8) in women. The most significant decreases in incidence rates were observed for stomach (4.7%), laryngeal (4.4%), and gallbladder cancers (3.5%), with parallel decreases in mortality rates (3.9%, 2.7% and 3.2%, respectively).InterpretationWe found a lower incidence of newly diagnosed cancer cases for Hungary compared to previous estimates, and decreasing trends in cancer incidence and mortality, in line with global findings and the declining prevalence of smoking.
Keywords
- cancer burden
- cancer incidence
- cancer mortality
- financial health insurance database
- real-wold data
- Hungary